Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Ikonisys SA (ALIKO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.52 0.00    0.00%
30/07 - Closed. Currency in EUR
Type:  Equity
Market:  France
ISIN:  FR00140048X2 
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1.52 - 1.52
Ikonisys 1.52 0.00 0.00%

Ikonisys SA Company Profile

 
Get an in-depth profile of Ikonisys SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

11

Equity Type

ORD

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review. Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.

Contact Information

Address 62 rue de Caumartin
Paris, 75009
France
Phone -
Fax -

Top Executives

Name Age Since Title
Pramod K. Srivastava 68 - Director
Alberto Calvo 53 - Director
Roberto Rettani 71 - Director
Vittorio Grazioli 67 - Director
Mario P. Crovetto 71 - GM, MD. CEO & Director
Mario Mauri 73 2022 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALIKO Comments

Write your thoughts about Ikonisys SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email